☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___ to ___ Commission File Number: 001-36305 SEMLER SCIENTIFIC, INC. Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or Indicate by check mark whether the registrant (1) has filed all reports required t ...

Financial Data and Key Metrics - Total revenues in Q1 2024 were $15.9 million, a decrease of 13% compared to Q1 2023 [5] - Fixed fee revenues were $7.1 million, a decrease of 24% year-over-year [5] - Variable fee revenues were $8 million, a decrease of 6% year-over-year [5] - Equipment and other revenues were $0.8 million, an increase of 140% year-over-year [33] - Operating expenses in Q1 2024 were $8.9 million, a decrease of 25% year-over-year, representing 56% of revenues compared to 66% in 2023 [6] - Pretax net income was $7.8 million compared to $6.6 million in the prior year [7] - Net income was $6.1 million or $0.88 per basic share and $0.78 per fully diluted share, compared to $5 million or $0.74 per basic share and $0.63 per fully diluted share in Q1 2023 [7] - Cash balance at March 31, 2024, was a record high of $62.9 million [7] Business Line Data and Key Metrics - The company's revenues are driven by sales of QuantaFlo for testing peripheral arterial disease (PAD) [5] - The three largest customers, including their related affiliates, comprised 45%, 25%, and 11% of quarterly revenue [6] - The company is pursuing an additional 510(k) clearance from the FDA for QuantaFlo to broaden its utility for a wider array of cardiovascular diseases, with anticipated clearance in the second half of 2024 [8][40] Market Data and Key Metrics - The Centers for Medicare and Medicaid Services (CMS) announced the three-year phase-in of the removal of the HCC code relating to PAD without complications from the Medicare Advantage risk adjustment model, with 2024 being the first year of the phase-in [11] - The company expects revenues in 2024 to follow a similar cadence to 2023, with H1 more heavily weighted than H2 [11][44] Company Strategy and Industry Competition - The company is focused on expanding its customer base for PAD and exploring inorganic growth initiatives to diversify its product portfolio [17][49] - The company is committed to research and development to enhance existing products and data services, with a long-term vision of extending its reach to additional cardiovascular applications [36] - The company aims to establish QuantaFlo as the standard of care for PAD diagnosis and diversify its customer base by adding new medical centers and expanding within value-based care providers and the VA system [35] Management Commentary on Operating Environment and Future Outlook - The company achieved year-over-year earnings growth despite a regulatory-driven revenue decline from its PAD product [2] - The company anticipates a slight uptick in expenses as it prepares for the next phase of launching QuantaFlo with expanded use [12] - The company is encouraged by the continued testing for PAD, given the importance of early diagnosis and treatment [11] - The company believes its technology can play a central role in delivering healthier outcomes for patients and substantial economic value to customers [15] Other Important Information - The company has a $20 million share buyback authorization, with $5 million already repurchased and $15 million remaining [45] Q&A Session Summary Question: Timing and process for receiving the 510(k) clearance - The company anticipates receiving clearance in the second half of 2024 and will start marketing the expanded use of QuantaFlo to existing customers upon approval [40][50] Question: Current demand environment and potential customer loss - The company has seen continued testing for PAD but also some cleanup of underutilized units. The clinical value of testing remains the same, and the company has a robust pipeline for growth [23][24] Question: Potential uses of cash for inorganic growth opportunities - The company is exploring inorganic growth initiatives, including strategic partnerships and acquisitions, to diversify its product portfolio [17][51] Question: Revenue cadence for 2024 - The company expects revenues to follow a similar cadence to 2023, with H1 more heavily weighted than H2 [44] Question: Specific conditions QuantaFlo might identify with the 510(k) clearance - The expanded use of QuantaFlo will focus on heart dysfunction, with specific wording to be released upon FDA clearance [41]

Exhibit 99.1 Semler Scientific® Reports First Quarter 2024 Financial Results 2024 Q1 highlights compared to the corresponding period of 2023: Santa Clara, CA – May 7, 2024 – Semler Scientific, Inc. (Nasdaq: SMLR), a company that develops, manufactures and markets innovative medical products and services that assist in evaluating and treating chronic diseases, today reported financial results for the first quarter ended March 31, 2024. "We had a very strong quarter of cash generation despite the regulatory-d ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to Commission file number: 001-36305 SEMLER SCIENTIFIC, INC. (Exact name of registrant as specified in its charter) Delaware 26-1367393 (State or other ju ...

Semler Scientific, Inc. (NASDAQ:SMLR) Q4 2023 Earnings Conference Call March 5, 2024 4:30 PM ET Company Participants Doug Murphy-Chutorian - Chief Executive Officer Renae Cormier - Chief Financial Officer Jennifer Oliva Herrington - Chief Operating Officer Conference Call Participants Brooks O'Neil - Lake Street Capital Markets Operator Good afternoon, and welcome to the Semler Scientific 2023 Fourth Quarter Financial Results Conference Call. All participants will be in a listen-only mode [Operator Instruct ...

[Executive Summary & Business Update](index=1&type=section&id=Executive%20Summary%20%26%20Business%20Update) This section provides an executive summary of Semler Scientific's business, product focus, and key financial highlights for Q4 and full-year 2023 [Company Profile & Product Focus](index=1&type=section&id=About%20Semler%20Scientific%2C%20Inc.) Semler Scientific develops innovative medical products for chronic diseases, featuring FDA-approved QuantaFlo® for arterial blood flow measurement, and is pursuing expanded indications and strategic investments - Semler Scientific focuses on innovative medical products and services for chronic diseases, with its flagship product **QuantaFlo®**, an **FDA-approved** patented point-of-care device, measuring arterial blood flow to aid in cardiovascular disease diagnosis[1](index=1&type=chunk)[17](index=17&type=chunk) - QuantaFlo® aids in diagnosing cardiovascular diseases like Peripheral Artery Disease (PAD), and the company is seeking new **510(k) clearance** to expand its diagnostic applications for other cardiovascular conditions[2](index=2&type=chunk)[17](index=17&type=chunk)[18](index=18&type=chunk) - Semler Scientific made minority equity investments in Mellitus, SYNAPS Dx, and Monarch Medical Technologies LLC, whose product **EndoTool®** is used for inpatient glucose management[17](index=17&type=chunk) [2023 Q4 and Full Year Highlights](index=1&type=section&id=2023%20Q4%20and%20full%20year%20highlights) Semler Scientific achieved consistent year-over-year revenue and net income growth in Q4 and FY2023, driven by QuantaFlo® sales, reaching a record high cash balance - Revenue for both **Q4 and full-year 2023** achieved year-over-year growth[1](index=1&type=chunk)[10](index=10&type=chunk) - Net income for both **Q4 and full-year 2023** achieved year-over-year growth[1](index=1&type=chunk)[10](index=10&type=chunk) - Cash balance increased to **$57.3 million**, marking a record high for cash and cash equivalents[3](index=3&type=chunk)[10](index=10&type=chunk) [Detailed Financial Results](index=1&type=section&id=Detailed%20Financial%20Results) This section presents a detailed analysis of Semler Scientific's financial performance for FY2023 and Q4 2023, including income statements, balance sheets, and cash flow [FY2023 Performance](index=1&type=section&id=For%20the%20year%20ended%20December%2031%2C%202023%2C%20compared%20to%20the%20corresponding%20period%20of%202022) FY2023 saw strong financial growth for Semler Scientific, with total revenue up **20%** and net income up **44%**, primarily from variable fee software license revenue, alongside improved operating efficiency despite increased cost of revenue FY2023 Key Financial Data (Y-o-Y) | Metric | 2023 (million USD) | 2022 (million USD) | Y-o-Y Growth (%) | | :-------------------------------- | :------------------ | :------------------ | :--------- | | Revenue | $68.2 | $56.7 | 20% | | Fixed Fee Software License Revenue | $37.3 | $34.0 | 9% | | Variable Fee Software License Revenue | $29.0 | $21.3 | 36% | | Other Product Sales | $1.9 | $1.4 | 42% | | Cost of Revenue | $7.0 | $4.3 | 64% | | Total Operating Expenses | $45.9 | $39.5 | 16% | | Income Before Income Taxes | $24.1 | $17.7 | 36% | | Net Income | $20.6 | $14.3 | 44% | | Basic Earnings Per Share | $3.06 | $2.13 | 44% | | Diluted Earnings Per Share | $2.63 | $1.79 | 47% | - FY2023 cost of revenue included a **$2.5 million** write-off of prepaid software licenses for Insulin Insights, contributing to a **64%** year-over-year increase in cost of revenue[3](index=3&type=chunk)[4](index=4&type=chunk) - Operating expenses as a percentage of revenue decreased from **70%** in 2022 to **67%** in 2023[4](index=4&type=chunk) [Q4 2023 Performance](index=1&type=section&id=For%20the%20fourth%20quarter%20ended%20December%2031%2C%202023%2C%20compared%20to%20the%20corresponding%20period%20of%202022) Q4 2023 revenue grew **9%** and net income increased **31%**, driven by variable fee software licenses and other product sales, despite a **29%** decline in pre-tax income due to higher costs Q4 2023 Key Financial Data (Y-o-Y) | Metric | Q4 2023 (million USD) | Q4 2022 (million USD) | Y-o-Y Growth (%) | | :-------------------------------- | :------------------------ | :------------------------ | :--------- | | Revenue | $15.1 | $13.8 | 9% | | Fixed Fee Software License Revenue | $8.8 | $9.0 | -2% | | Variable Fee Software License Revenue | $5.8 | $4.5 | 28% | | Other Product Sales | $0.5 | $0.3 | 71% | | Cost of Revenue | $3.4 | $1.2 | 186% | | Total Operating Expenses | $12.5 | $10.2 | 23% | | Income Before Income Taxes | $2.8 | $4.0 | -29% | | Net Income | $4.2 | $3.2 | 31% | | Basic Earnings Per Share | $0.62 | $0.48 | 29% | | Diluted Earnings Per Share | $0.55 | $0.41 | 34% | - Q4 2023 cost of revenue included a **$2.5 million** write-off of prepaid software licenses for Insulin Insights, leading to a **186%** year-over-year increase in cost of revenue[5](index=5&type=chunk)[9](index=9&type=chunk) - Operating expenses as a percentage of revenue increased from **74%** in Q4 2022 to **83%** in Q4 2023[9](index=9&type=chunk) [Customer Concentration](index=2&type=section&id=Customer%20Concentration) Semler Scientific maintains significant customer concentration, with its top two clients contributing **71%** of FY2023 revenue and top three clients **80%** of Q4 2023 revenue - In FY2023, Semler Scientific's two largest customers (including affiliates) accounted for **36%** and **35%** of total revenue, respectively, totaling **71%**[5](index=5&type=chunk) - In Q4 2023, the top three customers (including affiliates) accounted for **37%**, **32%**, and **11%** of total revenue, respectively, totaling **80%**[6](index=6&type=chunk) [Statements of Income (Unaudited)](index=4&type=section&id=Statements%20of%20Income) The unaudited statements of income detail Q4 and full-year 2023 revenue, operating expenses, and net income, noting a **$2.5 million** cost of revenue write-off and a shift to income tax benefit in Q4 Statements of Income Summary (Unaudited, in thousand USD) | Metric | Q4 2023 | Q4 2022 | FY2023 | FY2022 | | :-------------------------------- | :------------- | :------------- | :--------- | :--------- | | Revenue | $15,056 | $13,794 | $68,184 | $56,686 | | Cost of Revenue | $3,384 | $1,182 | $6,984 | $4,252 | | Total Operating Expenses | $12,534 | $10,178 | $45,928 | $39,483 | | Operating Income | $2,522 | $3,616 | $22,256 | $17,203 | | Income Before Income Taxes | $2,814 | $3,956 | $24,100 | $17,692 | | Income Tax Expense (Benefit) | $(1,407) | $740 | $3,517 | $3,367 | | Net Income | $4,221 | $3,216 | $20,583 | $14,325 | | Basic Earnings Per Share | $0.62 | $0.48 | $3.06 | $2.13 | | Diluted Earnings Per Share | $0.55 | $0.41 | $2.63 | $1.79 | [Balance Sheets (Unaudited)](index=5&type=section&id=Balance%20Sheets) As of December 31, 2023, Semler Scientific's balance sheet shows significant total asset growth, driven by increased cash and equivalents, alongside reduced total liabilities and a substantial rise in stockholders' equity Balance Sheet Summary (Unaudited, in thousand USD) | Metric | December 31, 2023 | December 31, 2022 | Change | | :-------------------------------- | :------------- | :------------- | :----- | | Cash and Cash Equivalents | $57,200 | $23,014 | +$34,186 | | Short-Term Investments | $0 | $20,073 | -$20,073 | | Accounts Receivable, Net | $6,125 | $3,884 | +$2,241 | | Total Current Assets | $65,944 | $48,908 | +$17,036 | | Total Assets | $78,065 | $62,693 | +$15,372 | | Total Current Liabilities | $6,200 | $6,857 | -$657 | | Total Stockholders' Equity | $71,795 | $55,676 | +$16,119 | [Statements of Cash Flows (Unaudited)](index=6&type=section&id=Statements%20of%20Cash%20Flows) FY2023 saw strong **$21.3 million** net cash inflow from operations and a positive shift in investing activities, leading to a **$34.3 million** increase in cash and equivalents, reaching **$57.3 million** at year-end Statements of Cash Flows Summary (Unaudited, in thousand USD) | Metric | FY2023 | FY2022 | | :-------------------------------- | :--------- | :--------- | | Net Income | $20,583 | $14,325 | | Net Cash Provided by Operating Activities | $21,330 | $17,463 | | Net Cash Provided by (Used in) Investing Activities | $18,396 | $(26,835) | | Net Cash Used in Financing Activities | $(5,408) | $(4,937) | | Net Increase (Decrease) in Cash | $34,318 | $(14,309) | | Cash, Cash Equivalents, and Restricted Cash at End of Period | $57,332 | $23,014 | - Investing activities shifted from a net cash outflow of **$26.8 million** in 2022 to a net cash inflow of **$18.4 million** in 2023, primarily due to proceeds from maturities of short-term investments[16](index=16&type=chunk) - Taxes paid increased to **$4.06 million** in 2023, up from **$2.40 million** in 2022[16](index=16&type=chunk) [Corporate Information](index=2&type=section&id=Corporate%20Information) This section provides corporate information, including conference call details, forward-looking statements, and investor contact information [Conference Call Details](index=2&type=section&id=Notice%20of%20Conference%20Call) Semler Scientific held a conference call on March 5, 2024, to discuss Q4 and full-year 2023 financial results and provide business updates, with details for participation - The company held a conference call on **March 5, 2024, at 4:30 PM ET**, to discuss Q4 and full-year 2023 results and recent strategies[7](index=7&type=chunk) - Participants can join the conference call via online pre-registration or by dialing the provided domestic and international phone numbers[8](index=8&type=chunk)[11](index=11&type=chunk) - A replay of the conference call will be archived on Semler Scientific's website[11](index=11&type=chunk) [Forward-Looking Statements](index=7&type=section&id=Forward-Looking%20Statements) This section contains standard forward-looking statements, including intentions to seek new FDA 510(k) clearances for QuantaFlo®, subject to risks like reimbursement policy changes and regulatory approvals - The press release contains forward-looking statements, including explicit or implicit statements about seeking new **510(k) clearance** for **QuantaFlo®** to expand its indications for use[18](index=18&type=chunk) - These forward-looking statements are subject to various risks and uncertainties, such as whether insurance plans and customers will continue to license its cardiovascular testing products, changes in reimbursement policies, and the ability to successfully obtain **FDA expanded indication clearance**[18](index=18&type=chunk) - Semler Scientific undertakes no obligation to update or revise these statements unless required by law[18](index=18&type=chunk) [Investor Contact](index=7&type=section&id=INVESTOR%20CONTACT) Renae Cormier, Chief Financial Officer, serves as Semler Scientific's designated investor contact - Investor Contact: Renae Cormier, Chief Financial Officer, reachable at ir@semlerscientific.com[19](index=19&type=chunk)

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Commission File Number: 001-36305 SEMLER SCIENTIFIC, INC. FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___ to ___ (Exact name of registrant as specified in its charter) Delaware 26-1367393 (St ...

Semler Scientific, Inc. (NASDAQ:SMLR) Q3 2023 Earnings Conference Call November 9, 2023 4:30 PM ET Company Participants Doug Murphy-Chutorian – Chief Executive Officer Renae Cormier – Chief Financial Officer Jennifer Oliva Herrington – Chief Operating Officer Conference Call Participants Aaron Wukmir – Lake Street Capital Markets Herbert Semler – Semler Health Operator Good afternoon, and welcome to the Semler Scientific 2023 Third Quarter Financial Results Conference Call. All participants will be in a lis ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___ to ___ Commission File Number: 001-36305 SEMLER SCIENTIFIC, INC. (Exact name of registrant as specified in its charter) Delaware 26-1367393 (877) 77 ...

Financial Data and Key Metrics Changes - Total revenue in Q2 2023 was $18.6 million, an increase of 25% compared to Q2 2022, driven by continued sales of QuantaFlo for PAD testing [40] - Pre-tax net income was $7.7 million, an increase of $2.5 million or 48% year-over-year, while net income was $5.9 million, or $0.88 per basic share and $0.75 per diluted share, an increase of 44% year-over-year [43] Business Line Data and Key Metrics Changes - Fixed fee revenues were $9.6 million, an increase of 13% year-over-year, while variable fee revenues were $8.4 million, an increase of 39% year-over-year [41] - Equipment and other revenues were $600,000, an increase of 128% year-over-year, indicating strength in the fee per test market [42] Market Data and Key Metrics Changes - The two largest customers comprised 37% and 34% of quarterly revenues, highlighting reliance on major clients [43] - There is strong demand from home risk assessment customers using QuantaFlo for PAD during in-home examinations [41] Company Strategy and Development Direction - The company aims to maintain and enhance current revenue opportunities and profitability by reinvesting in emerging growth opportunities, particularly focusing on new customers for QuantaFlo [4] - A strategic plan to streamline operations and reduce employee headcount by approximately 30% by September 15, 2023, is in place to drive operational efficiency [2] Management's Comments on Operating Environment and Future Outlook - Management noted that it is difficult to predict customer reactions to pending changes in the risk model for PAD from CMS due to various factors at play in the market [17] - The company is committed to maintaining investments in research and development to stay at the forefront of innovation [5] Other Important Information - The company anticipates incurring severance costs in the range of $700,000 to $900,000, which are expected to result in a reduction in quarterly operating expenses of approximately $1.5 million to $2 million [3] - The company is exploring inorganic growth initiatives to diversify its product portfolio [11] Q&A Session Summary Question: Reaction of health plans and fee per test customers to CMS changes - Management indicated that it is too early to speculate on potential impacts to customers, but testing is currently at an increased rate [18] Question: Customer interest in heart dysfunction product and revenue expectations - Management confirmed positive feedback from initial installations of QuantaFlo HD, but noted that market uptake will take time and they are not providing specific guidance on revenue [19][20] Question: Priorities regarding downsizing and streamlining initiatives - Management explained that the focus is on automation and technology improvements, leading to a reduced need for certain staff areas, and emphasized the importance of capitalizing on emerging market opportunities [22]